| |
Species: |
Dog |
Strain/breeder: |
Beagle / Marshall |
Sex: |
Male (8A), female (8B) |
Age: |
12-14 Months |
Study type: |
Oral, 4 weeks treatment |
Treatment: |
Anticancer compound, high dose |
Animal status: |
Scheduled sacrifice: 8A: after 4 weeks treatment
8B: after an additional 6-week recovery period
|
Clinical findings: |
Salivation, vomiting, body weight loss, anemia, leukopenia, increased liver enzymes |
Organ(s): |
Liver |
Macroscopic finding(s): |
None |
Staining: |
H&E |
|
|
Fig. 1 (130k)
Fig. 2 (132k)
|
|